Effect of VExUS Score on Postoperative Pulmonary Complications in Elderly Patients

Effect of VExUS Score-Guided Intraoperative Goal-Directed Fluid Therapy on Postoperative Pulmonary Complications in Elderly Patients Undergoing McKeown Minimally Invasive Esophagectomy: A Randomized Controlled Trial

Brief Summary This clinical trial aims to evaluate whether perioperative goal-directed fluid therapy (GDFT) targeting a venous excess ultrasound (VExUS) score of 1 can reduce postoperative pulmonary complications (PPCs) in elderly patients undergoing McKeown minimally invasive esophagectomy (MIE). The study will also assess postoperative organ microcirculatory perfusion and quality of recovery.

Key research questions the trial seeks to answer include:

Does VExUS score-guided GDFT reduce the incidence of PPCs in elderly patients following McKeown MIE? Do participants receiving VExUS-guided GDFT achieve better clinical outcomes? Investigators will compare VExUS score-targeted GDFT with fluid therapy guided by the standard Vigileo-FloTrac™ system, to determine if the VExUS-guided approach reduces the occurrence of postoperative pulmonary complications in elderly patients.

Participant assessments and data collection include:

VExUS score assessment at four time points: preoperatively, after thoracic phase of surgery, after abdominal phase of surgery, and at the end of surgery. Concomitant measurements will include capillary refill time (CRT, in minutes), perfusion index (PI), blood lactate level (Lac, in mmol/L), and central venous oxygen saturation (ScvO₂, in percent).

Postoperative lung ultrasound score assessment. Recording of clinical outcomes including length of intensive care unit (ICU) stay (in days), postoperative hospital length of stay (in days), 30-day postoperative readmission rate due to pulmonary complications (in percent), and in-hospital postoperative mortality rate (in percent).

Study Overview

• Status: Not yet recruiting
• Conditions: Esophageal Cancer (EsC); Postoperative Pulmonary Complications (PPCs)
• Intervention / Treatment: Procedure: VExUS Score-Guided Intraoperative Goal-Directed Fluid Therapy

Detailed Description

1. Background In China, esophageal cancer (EsC) is a common malignancy of the digestive tract, and surgery remains the primary treatment modality . Currently used esophageal tumor resection approaches include McKeown esophagectomy, Ivor Lewis esophagectomy, and Sweet esophagectomy, among others. Among these, thoracoscopic three-incision McKeown minimally invasive esophagectomy (McKeown MIE) offers advantages in lymph node dissection and is therefore one of the commonly used surgical approaches for esophageal cancer. Postoperative pulmonary complications (PPCs) are the most frequent type of complication following esophagectomy, accounting for 28.9%-50% of all complications , and have been demonstrated to be associated with in-hospital mortality , prolonged hospital stay, and increased medical costs .

   With the implementation of enhanced recovery after surgery (ERAS) protocols, perioperative fluid management in esophageal cancer surgery has become increasingly important. Inappropriate perioperative fluid volume is an independent risk factor for lung injury . Veelo et al. emphasized that goal-directed hemodynamic therapy can significantly reduce the incidence of postoperative pneumonia . In the absence of continuous hemodynamic monitoring, total intraoperative fluid infusion exceeding 5000 mL should be avoided in patients without ongoing blood loss . Inappropriate intraoperative blood transfusion increases the incidence of PPCs, elevates postoperative mortality, and leads to poorer long-term prognosis due to higher tumor recurrence rates .

   Therefore, perioperative fluid management is particularly critical in McKeown MIE. In patients undergoing this procedure, perioperative fluid overload can lead to: (a) increased capillary hydrostatic pressure, and (b) accumulation of excess fluid in the alveolar space, causing alveolar compression, collapse, and exudation, resulting in increased dead space ventilation and intrapulmonary shunt, which in turn induces pulmonary venous congestion and interstitial pulmonary edema. Conversely, inadequate fluid resuscitation may lead to insufficient organ perfusion, exacerbating organ injury such as acute kidney injury (AKI). The traditional "empiric fluid therapy" approach is gradually being replaced by goal-directed fluid therapy (GDFT). Thus, GDFT has become an important target for preventing PPCs in elderly patients undergoing McKeown MIE.

   GDFT aims to optimize end-organ perfusion and improve tissue oxygen delivery through precise fluid administration, thereby reducing the risk of PPCs. Existing GDFT strategies include fluid therapy based on dynamic hemodynamic parameters (Vigileo-FloTrac™), central venous pressure (CVP)-guided fluid therapy , perfusion index-guided therapy, and transesophageal echocardiography (TEE)-guided fluid therapy. However, compared with the Venous Excess Ultrasound (VExUS) score, these monitoring modalities cannot accurately and real-time reflect overall venous congestion, nor can they provide integrated monitoring of the matching between venous return driving pressure and right ventricular function.

   The VExUS score is an emerging bedside ultrasound-based volume quantification tool that evaluates important capacitance veins, including the inferior vena cava diameter, and the hepatic, portal, and renal veins. By comprehensively monitoring their vessel diameter, resistance indices, and Doppler waveforms, it provides a real-time, non-invasive, and direct reflection of the match between fluid therapy and patient status .

   Elevated venous pressure is associated with poor prognosis and prolonged intensive care unit (ICU) stay . This non-invasive assessment of venous congestion may become an important bedside tool for clinicians. This novel technique has several potential applications in the ICU , including guiding diuretic therapy in patients with cardiogenic shock and individualizing fluid resuscitation in patients with septic shock . Studies have demonstrated that VExUS-guided fluid therapy reduces circulation-related complications in patients undergoing major abdominal surgery and in those with heart failure. However, evidence regarding its application in elderly patients undergoing esophageal cancer surgery remains lacking. Elderly patients are characterized by reduced vascular elasticity, diminished renal functional reserve, and poor tolerance to fluid fluctuations. In elderly patients undergoing McKeown MIE, extensive surgical wounds, prolonged one-lung ventilation, and impaired pulmonary venous return increase the risk of pulmonary congestion. Fluid responsiveness and lung-protective strategies are closely related to fluid therapy. Therefore, the application of the VExUS score - a "cardiac congestion score" - in this patient population may effectively prevent PPCs.

   This randomized controlled trial aims to investigate the effect of perioperative GDFT targeting a VExUS score of 1 on postoperative PPCs in elderly patients undergoing McKeown MIE, with the goal of providing a more precise and safer fluid management strategy for this patient population. This study holds important clinical significance for reducing postoperative pulmonary complications, improving prognosis, and advancing perioperative fluid management concepts.

2. Objectives and Expected Outcomes 2.1 Objectives Primary Objective: To verify whether GDFT based on the VExUS score can reduce the incidence of PPCs in elderly patients after McKeown MIE, compared with classic Vigileo-FloTrac™ system-guided fluid therapy.

   Secondary Objectives: To explore the effects of VExUS score-based GDFT on postoperative lung ultrasound score (LUS), duration of postoperative mechanical ventilation, length of ICU stay, total length of hospital stay, 30-day readmission rate due to pulmonary complications, and in-hospital postoperative mortality in elderly patients undergoing McKeown MIE. Additionally, to identify important risk factors affecting postoperative pulmonary complications in this population within the framework of GDFT-based perioperative management.

   2.2 Expected Outcomes Through clinical intervention, data analysis, and synthesis, this study aims to clarify the efficacy of VExUS score-based GDFT in preventing pulmonary complications in elderly patients after McKeown MIE, and to develop a comprehensive understanding of the associated risk factors. These findings will provide an optimized perioperative fluid management strategy for this patient population, improve postoperative recovery and overall prognosis, offer a reference for early screening and future rational intervention in this high-risk group, and ultimately enhance the quality of postoperative recovery.

3. Study Design and Methods 3.1 Study Design This randomized controlled clinical trial strictly adheres to the Declaration of Helsinki [19] and employs a randomized, controlled, prospective design, following the ethical principles of clinical trials and the CONSORT guidelines for the conduct and reporting of randomized controlled trials. The study will be registered with the Chinese Clinical Trial Registry.

3.2 Study Population Ethical approval for this study will be submitted to the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. Patients scheduled to undergo thoracoscopic three-incision McKeown MIE will be recruited from the Department of Anesthesiology, the First Affiliated Hospital of Chongqing Medical University, from February 2026 to July 2026. An estimated total of 126 patients will be enrolled.

3.3 Allocation, Randomization, and Blinding Enrolled subjects will be allocated in a 1:1 ratio to the VExUS score-guided GDFT group (Group V) and the control group (Group C). Randomization will be performed using a permuted block design (block size of 4) by an independent researcher not involved in patient management, using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Allocation concealment will be achieved using sequentially numbered, opaque, sealed envelopes. On the day of surgery, a research nurse not involved in anesthesia management or data collection will open the next envelope before induction and inform the attending anesthesiologist of the group assignment. All VExUS assessments will be performed by the same senior ultrasonographer to ensure procedural consistency. To preserve internal validity, the anesthesiologists managing intraoperative care, the postoperative outcome assessors, and the data analysts will all remain blinded to group allocation.

3.4 Study Methods and Procedures 3.4.1 Anesthesia Management All enrolled patients must provide written informed consent, and the study protocol must be approved by the hospital ethics committee. One day before surgery, the attending anesthesiologist will conduct a preoperative visit to assess the patient's baseline condition. Patients will undergo standard preoperative fasting for 6-8 h and abstain from clear liquids for 2 h. All patients will receive routine preoperative preparation with complete preoperative examinations. Blood pressure and blood glucose levels in patients with comorbidities such as hypertension and diabetes will be controlled within ranges appropriate for surgery.

Both groups will receive standardized anesthesia management as follows:

Anesthesia induction: Midazolam (0.03 mg/kg), etomidate (0.3 mg/kg), sufentanil (0.5 μg/kg), and rocuronium (0.6 mg/kg).

After induction, a double-lumen endotracheal tube or bronchial blocker will be placed for one-lung ventilation (OLV), and correct positioning will be confirmed by fiberoptic bronchoscopy. After the patient is repositioned to the left lateral decubitus position, a paravertebral nerve block (T4-T6) will be performed using 20 mL of 0.25% ropivacaine. All nerve block procedures will be performed by the same group of senior anesthesiologists.

Anesthesia maintenance: Remifentanil (0.05-0.2 μg/kg/min), propofol (4-6 mg/kg/h), sevoflurane (1-2%), with cisatracurium added as needed. Doses will be adjusted according to depth of anesthesia, with the bispectral index (BIS) maintained at 40-60.

At the time of transition from OLV to two-lung ventilation and at the end of surgery, thorough tracheal suctioning will be performed, followed by an alveolar recruitment maneuver (ARM) (30 cmH₂O for 30 s).

Patient-controlled analgesia (PCA): Sufentanil 2 μg/kg diluted with normal saline to a total volume of 100 mL, administered at a background infusion rate of 2 mL/h, with a bolus dose of 2 mL and a lockout interval of 15 min.

At the end of surgery, the double-lumen endotracheal tube will be exchanged for a single-lumen tube in the operating room, and patients will be transferred to the thoracic surgery ICU intubated. Spontaneous breathing will be allowed to recover, and tracheal extubation will be performed according to extubation criteria. The same anesthesiologist will be responsible for perioperative anesthesia management for all patients in this study; another staff member will collect all perioperative data. Postoperative pulmonary complications will be assessed by thoracic surgeons not involved in the surgery or anesthesia.

Lung-protective ventilation strategy: OLV tidal volume (VT): 4-6 mL/kg; respiratory rate (RR): 12-18 breaths/min; fraction of inspired oxygen (FiO₂): 50%-100% . The lowest driving pressure (ΔP) will be targeted at 10-15 cmH₂O: PEEP will be increased from 1 cmH₂O to 10 cmH₂O, with each PEEP level maintained for 10 respiratory cycles. The ΔP of the last respiratory cycle at each level will be recorded, and the PEEP associated with the lowest ΔP will be selected and maintained throughout OLV . PETCO₂ will be maintained at 35-45 mmHg, and SpO₂ > 95%.

3.7.2 Study Interventions

1. Control Group (Group C): GDFT guided by the Vigileo-FloTrac™ system (Edwards Lifesciences, USA). The radial artery will be cannulated and connected to the Vigileo-FloTrac™ system to monitor stroke volume variation (SVV) and cardiac index (CI). Maintenance fluids will be administered at 2-3 mL/kg/h. Targets: SVV: 10%-12%; CI: 2.5-4.0 L/min/m²; systemic vascular resistance index (SVRI): 1900-2400 dyn·s/cm⁵; CVP: 8-12 cmH₂O.

   When SVV > 12% and CVP < 12 cmH₂O, a colloid bolus of 3 mL/kg will be infused over 10 min for volume expansion. If, after volume expansion, SVV decreases to < 12% or CI fluctuation ≤ 10%, CI will be assessed: if CI > 2.5 L/min/m², reassessment will be performed after 5 min; if CI ≤ 2.5 L/min/m², dopamine will be infused at 3 μg/kg/min until CI > 2.5 L/min/m². If urine output < 0.5 mL/kg/h, 150-200 mL of fluid will be administered; if after 30 min urine output remains < 0.5 mL/kg/h, furosemide 10 mg will be administered intravenously until urine output reaches 0.5-1 mL/kg/h .

2. Experimental Group (Group V): VExUS scoring will be performed by an ultrasonographer proficient in ultrasound techniques (experience with > 100 cases and certified by the Chinese Medical Doctor Association Ultrasound Branch). Assessment time points: before surgery, after thoracic manipulation, after abdominal manipulation, and at the end of surgery.

• Study Type: Observational
• Enrollment (Estimated): 126

Contacts and Locations

• Study Contact: Name: Lihua Li Peng, Doctor; Phone Number: +8615823443968 +86 89011876; Email: plhcqmu@163.com
• Study Contact Backup: Name: Mengninng Wan, Doctor; Phone Number: +8615215151223 +86 89011876; Email: 1029211312@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study protocol has been submitted for ethical approval to the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. A total of 126 patients scheduled for elective thoracoscopic three-incision radical esophagectomy (McKeown MIE) will be recruited from the Department of Anesthesiology, First Affiliated Hospital of Chongqing Medical University between February 2026 and July 2026.

Description

Inclusion Criteria:

• Age between 65 and 80 years old
• Scheduled for elective McKeown MIE
• ASA physical status classification I to III
• Body mass index (BMI) between 18 kg/m² and 30 kg/m² (exclusive of 18 kg/m²)

Exclusion Criteria:

• Respiratory failure (SaO₂ < 60 mmHg and/or PaCO₂ > 50 mmHg)
• Severe cardiac dysfunction (NYHA class III-IV)
• Angina pectoris within the past 3 months or acute myocardial infarction (STEMI/NSTEMI) within the past 6 months
• Pulmonary hypertension (pulmonary artery systolic pressure, PASP > 35 mmHg)
• Moderate to severe tricuspid stenosis/regurgitation (valve orifice area < 1.5 cm² / vena contracta width ≥ 0.3 cm)
• Decompensated cirrhosis (Child-Pugh class ≥ B)
• Chronic kidney disease (CKD stage ≥ 3a) (estimated glomerular filtration rate, eGFR < 45 mL/min/1.73 m²)
• Cognitive impairment (Mini-Mental State Examination, MMSE < 27) and inability to cooperate with follow-up

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of postoperative pulmonary complications (PPCs) (%)	Censoring will be performed at 30 days, with time to event defined as the time from surgery to ICU admission and discharge. Patients who die in the ICU or before discharge will be censored as not discharged at 30 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Postoperative Lung Ultrasound Score (LUS)（points）		Lung ultrasound score assessed at 1 hour postoperatively
Duration of Mechanical Ventilation	Time from surgery completion to tracheal extubation (in minutes)	From time of surgery completion to tracheal extubation, assessed up to 72 hours postoperatively
Duration of Non-Invasive Ventilation / High-Flow Nasal Cannula Use	Total duration of NIV or HFNC support in minutes, from surgery completion to discontinuation	From time of surgery completion to discontinuation of NIV or HFNC support, assessed up to 72 hours postoperatively
Oxygenation Index (PaO₂/FiO₂)(PaO₂/FiO₂ ratio)		Oxygenation index measured at three time points: at the end of surgery, at extubation, and 24 hours postoperatively
Capillary Refill Time (CRT)	Capillary refill time measured in seconds at four perioperative time points	Baseline (preoperatively), immediately after thoracic manipulation, immediately after abdominal manipulation, and at surgery completion (skin closure)
Peripheral Perfusion Index (PI)(%)	Capillary refill time measured in seconds at four perioperative time points	Baseline (preoperatively), immediately after thoracic manipulation, immediately after abdominal manipulation, and at surgery completion (skin closure)
Lactic Acid (Lac)(mmol/L)	Capillary refill time measured in seconds at four perioperative time points	Baseline (preoperatively), immediately after thoracic manipulation, immediately after abdominal manipulation, and at surgery completion (skin closure)
Central Venous Oxygen Saturation (ScvO₂)(%)	Capillary refill time measured in seconds at four perioperative time points	Baseline (preoperatively), immediately after thoracic manipulation, immediately after abdominal manipulation, and at surgery completion (skin closure)
Length of ICU Stay	Total duration of intensive care unit stay in days, from surgery completion to ICU discharge	From time of surgery completion to ICU discharge, assessed up to 30 days postoperatively
Length of Postoperative Hospital Stay(days)	Total duration of hospital stay in days, from surgery completion to discharge	From time of surgery completion to hospital discharge, assessed up to 30 days postoperatively
30-Day Readmission Rate Due to Pulmonary Complications(%)		Proportion of patients readmitted to hospital within 30 days due to pulmonary complications
In-Hospital Postoperative Mortality	Proportion of patients who died during the index hospitalization following surgery	From time of surgery completion to hospital discharge, assessed up to 30 days postoperatively

Collaborators and Investigators

• Sponsor: First Affiliated Hospital of Chongqing Medical University
• Investigators: Study Director: Juying Jin

Publications and helpful links

General Publications

• Kroenke K, Lawrence VA, Theroux JF, Tuley MR. Operative risk in patients with severe obstructive pulmonary disease. Arch Intern Med. 1992 May;152(5):967-71.
• Oba Y, Salzman GA. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury. N Engl J Med. 2000 Sep 14;343(11):813; author reply 813-4. No abstract available.
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2;381(9864):400-12. doi: 10.1016/S0140-6736(12)60643-6.
• Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol. 2012 May 10;30(14):1615-9. doi: 10.1200/JCO.2011.40.3568. Epub 2012 Apr 2.
• Bahlmann H, Halldestam I, Nilsson L. Goal-directed therapy during transthoracic oesophageal resection does not improve outcome: Randomised controlled trial. Eur J Anaesthesiol. 2019 Feb;36(2):153-161. doi: 10.1097/EJA.0000000000000908.
• Cheong I. Unconventional Echocardiographic Techniques for LVOT VTI Measurement in Critical Care Settings. J Clin Ultrasound. 2025 Jul-Aug;53(6):1418-1424. doi: 10.1002/jcu.24007. Epub 2025 Apr 12.
• Zhang YT, Chen Y, Shang KX, Yu H, Li XF, Yu H. Effect of Volatile Anesthesia Versus Intravenous Anesthesia on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: A Randomized Clinical Trial. Anesth Analg. 2024 Sep 1;139(3):571-580. doi: 10.1213/ANE.0000000000006814. Epub 2024 Feb 9.
• Nishio Y, Hara M, Oshita K, Jotaki S, Murotani K, Hiraki T. Relationship between Tryptase and Hypotension in Anaphylaxis during Anesthesia. Kurume Med J. 2024 Jul 2;70(1.2):19-27. doi: 10.2739/kurumemedj.MS7012012. Epub 2024 May 17.
• Wang D, Zhang Y, Wang S, Xue Y, Hu X, Gao J, Yu R, Zhuang Q, Cheng E, Li X. Correlation of lung ultrasound score with postoperative pulmonary complications in older adults undergoing thoracoscopic lobectomy: a prospective observational study. Eur J Med Res. 2025 Oct 21;30(1):999. doi: 10.1186/s40001-025-03271-2.
• Zhang Y, Zhan L, Li D, Huang G, Lan Y. Influence of goal-directed fluid therapy guided by the Vigileo-FloTracTM system on intestinal mucosal barrier function in elderly patients with colorectal cancer. Wideochir Inne Tech Maloinwazyjne. 2023 Sep;18(3):460-466. doi: 10.5114/wiitm.2023.128010. Epub 2023 Sep 1.
• Yang G, Hu C, Sun Z. An Updated Review of Driving-Pressure Guided Ventilation Strategy and Its Clinical Application. Biomed Res Int. 2022 Aug 2;2022:6236438. doi: 10.1155/2022/6236438. eCollection 2022.
• Park M, Ahn HJ, Kim JA, Yang M, Heo BY, Choi JW, Kim YR, Lee SH, Jeong H, Choi SJ, Song IS. Driving Pressure during Thoracic Surgery: A Randomized Clinical Trial. Anesthesiology. 2019 Mar;130(3):385-393. doi: 10.1097/ALN.0000000000002600.
• Shen Y, Zhong M, Wu W, Wang H, Feng M, Tan L, Wang Q. The impact of tidal volume on pulmonary complications following minimally invasive esophagectomy: a randomized and controlled study. J Thorac Cardiovasc Surg. 2013 Nov;146(5):1267-73; discussion 1273-4. doi: 10.1016/j.jtcvs.2013.06.043. Epub 2013 Aug 28.
• Brogger H. [The new Declaration of Helsinki]. Tidsskr Nor Laegeforen. 2023 Dec 14;143(1). doi: 10.4045/tidsskr.23.0798. Print 2024 Jan 23. No abstract available. Norwegian.
• Song J, Chen G, Lai D, Zhong L, Fan H, Hu W, Wang M, Hu C, Chen W, Ming Z, Gong S, Luo Q. Association between the Venous Excess Ultrasound (VExUS) score and acute kidney injury in critically ill patients with sepsis: a multicenter prospective observational study. Ann Intensive Care. 2025 Jul 23;15(1):105. doi: 10.1186/s13613-025-01529-w.
• Pierre-Gregoire G. VExUS score: optimizing its use in perioperative and critical care management. Crit Care. 2025 Nov 4;29(1):472. doi: 10.1186/s13054-025-05687-y.
• Brat K, Sova M, Homolka P, Plutinsky M, Genzor S, Pokorna A, Dosbaba F, Imrichova B, Chovanec Z, Mitas L, Mikulaskova M, Svoboda M, Olson L, Cundrle I; study group. Multimodal prehabilitation before lung resection surgery: a multicentre randomised controlled trial. Br J Anaesth. 2025 Jul;135(1):188-196. doi: 10.1016/j.bja.2025.03.018. Epub 2025 May 14.
• Reeh M, Ghadban T, Dedow J, Vettorazzi E, Uzunoglu FG, Nentwich M, Kluge S, Izbicki JR, Vashist YK. Allogenic Blood Transfusion is Associated with Poor Perioperative and Long-Term Outcome in Esophageal Cancer. World J Surg. 2017 Jan;41(1):208-215. doi: 10.1007/s00268-016-3730-8.
• Towe CW, Gulack BC, Kim S, Ho VP, Perry Y, Donahue JM, Linden PA. Restrictive Transfusion Practices After Esophagectomy Are Associated With Improved Outcome: A Review of the Society of Thoracic Surgeons General Thoracic Database. Ann Surg. 2018 May;267(5):886-891. doi: 10.1097/SLA.0000000000002231.
• Durkin C, Schisler T, Lohser J. Current trends in anesthesia for esophagectomy. Curr Opin Anaesthesiol. 2017 Feb;30(1):30-35. doi: 10.1097/ACO.0000000000000409.
• Kaufmann K, Heinrich S. Minimizing postoperative pulmonary complications in thoracic surgery patients. Curr Opin Anaesthesiol. 2021 Feb 1;34(1):13-19. doi: 10.1097/ACO.0000000000000945.
• Nozaki I, Mizusawa J, Kato K, Igaki H, Ito Y, Daiko H, Yano M, Udagawa H, Nakagawa S, Takagi M, Kitagawa Y. Impact of laparoscopy on the prevention of pulmonary complications after thoracoscopic esophagectomy using data from JCOG0502: a prospective multicenter study. Surg Endosc. 2018 Feb;32(2):651-659. doi: 10.1007/s00464-017-5716-5. Epub 2017 Aug 4.
• Klevebro F, Elliott JA, Slaman A, Vermeulen BD, Kamiya S, Rosman C, Gisbertz SS, Boshier PR, Reynolds JV, Rouvelas I, Hanna GB, van Berge Henegouwen MI, Markar SR. Cardiorespiratory Comorbidity and Postoperative Complications following Esophagectomy: a European Multicenter Cohort Study. Ann Surg Oncol. 2019 Sep;26(9):2864-2873. doi: 10.1245/s10434-019-07478-6. Epub 2019 Jun 10.
• Gottlieb-Vedi E, Kauppila JH, Mattsson F, Hedberg J, Johansson J, Edholm D, Lagergren P, Nilsson M, Lagergren J; FINEGO group. Extent of Lymphadenectomy and Long-term Survival in Esophageal Cancer. Ann Surg. 2023 Mar 1;277(3):429-436. doi: 10.1097/SLA.0000000000005028. Epub 2021 Jun 25.
• Okamura A, Watanabe M, Mine S, Nishida K, Kurogochi T, Imamura Y. Spirometric Lung Age Predicts Postoperative Pneumonia After Esophagectomy. World J Surg. 2016 Oct;40(10):2412-8. doi: 10.1007/s00268-016-3547-5.
• Seesing MFJ, Kingma BF, Weijs TJ, Ruurda JP, van Hillegersberg R. Reducing pulmonary complications after esophagectomy for cancer. J Thorac Dis. 2019 Apr;11(Suppl 5):S794-S798. doi: 10.21037/jtd.2018.11.75.
• Guinan EM, Bennett AE, Doyle SL, O'Neill L, Gannon J, Foley G, Elliott JA, O'Sullivan J, Reynolds JV, Hussey J. Measuring the impact of oesophagectomy on physical functioning and physical activity participation: a prospective study. BMC Cancer. 2019 Jul 12;19(1):682. doi: 10.1186/s12885-019-5888-6.

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: June 18, 2026
• First Submitted That Met QC Criteria: July 7, 2026
• First Posted (Actual): July 9, 2026

Study Record Updates

• Last Update Posted (Actual): July 9, 2026
• Last Update Submitted That Met QC Criteria: July 7, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Head and Neck Neoplasms; Esophageal Diseases; Esophageal Neoplasms
• Other Study ID Numbers: H50010300166

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Access to de-identified individual participant data (IPD) will be considered only when receiving legally valid, ethically approved requests that are in compliance with applicable data protection regulations and trial protocols.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No